About this event
While most COVID-19 patients are asymptomatic or display mild symptoms, some patients develop severe clinical symptoms. The pathogenic basis for this difference in disease severity among patients is poorly understood. Developing a better understanding of immune response across patient populations is crucial to understanding these differences and developing future vaccines capable of targeting novel COVID-19 variants.
This webinar will present cutting edge research and provide insights from the intersection between three areas of intense current focus – COVID-19 clinical research, single cell analysis and the measurement of T-cell response.
Attendees will leave with new approaches and ideas for achieving in-depth characterization of the CD8+ T-cell-mediated response to COVID-19 infection, which will support (1) the development of better molecular and targeted therapies and (2) the development of better vaccination strategies.
This webinar consists of 2 presentations, followed by a Q&A session.
Felix Schreibing, MD, Postdoctoral Fellow, Institute of Experimental Medicine and Systems Biology, University Hospital RWTH Aachen
Matilda Felicia Weywadt, Ph.D., Product Manager, Immudex
Felix Schreibing, MD, Postdoctoral Fellow, Institute of Experimental Medicine and Systems Biology, University Hospital RWTH Aachen
Matilda Felicia Weywadt, Ph.D., Product Manager, Immudex
Monica Hannini, Ph.D. Fellow, Institute of Experimental Medicine and Systems Biology, University Hospital RWTH Aachen
----------
This webinar has been made possible with the kind support of our partner, Immudex. To find out more about the dCODE Dextramer® technology, visit the Immudex website.
Hosted by
Front Line Genomics is a genomics-focused media company, with a social mission to deliver the benefits of genomics to patients faster. We organise the Festival of Genomics, digital events and webinars. We also produce reports and operate a content-rich website.